Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma.
Orally active kinase inhibitors such as Sorafenib are known to elicit cutaneous side effects in the majority of adult patients, whereas specific cutaneous complications of this agent have not been described in children so far. We here present the first pediatric case of Sorafenib-induced hand-foot-skin reaction and its successful topical therapy facilitating continuation of kinase inhibitor treatment.
Hütten
Matthias
M
Department of Pediatrics and Adolescent Medicine, RWTH Aachen University Hospital, Aachen, Germany.
Lassay
Lisa
L
Sachs
Bernhardt
B
Deutz
Peter
P
Mertens
Roland
R
Baron
Jens Malte
JM
Merk
Hans-Friedrich
HF
Ott
Hagen
H
D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D005533:Foot Dermatoses / Q000139:chemically induced* / Q000188:drug therapy; D006229:Hand Dermatoses / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib